Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development

Authors:
  • CCCong Chen
    Cong Chen
  • RBRobert A. Beckman
    Robert A. Beckman

Abstract
In late-stage oncology drug development, drug developers have to make two critical Go-No Go decisions. The first one is whether to proceed to the definitive Phase III investigation after a Phase II...

This publication has 13 references indexed in Scilit: